KRT17

Across TCGA pan-cancer cohorts, KRT17 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated KRT17 data layer compared with 22 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher KRT17 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated KRT17 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where KRT17 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	II,III,IV	1.000	0.875	.003	71	view →
LUAD	DFS	Median	All	0.416	0.945	<.001	55	view →
LSCC	OS	Tertile	III,IV	1.000	0.645	.009	12	view →
CCRCC	OS	Tertile	III,IV	0.660	1.000	.020	7	view →
PDAC	DFS	Median	All	0.735	0.844	.021	7	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

KRT17–HNSC (DFS)

Open the HNSC breakdown →